BTIG analyst Sam Eiber has commenced coverage of Evolus (EOLS, Financial), a company specializing in performance beauty within the cash-pay medical aesthetics sector, with a Buy rating and a price target of $21. The analyst emphasizes Evolus’ distinct approach as a non-therapeutic, cash-pay entity, which allows it to sidestep third-party payer reimbursement issues. This strategy grants the company enhanced pricing flexibility and the capacity to reinvest in provider practices via co-branded marketing efforts.
BTIG has identified multiple avenues through which Evolus could achieve its ambitious objective of generating at least $700 million in revenue and achieving a non-GAAP operating income margin of no less than 20%. The report suggests that Evolus' innovative market strategy positions it well for potential growth and profitability in the future.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Evolus Inc (EOLS, Financial) is $24.00 with a high estimate of $27.00 and a low estimate of $20.00. The average target implies an upside of 137.39% from the current price of $10.11. More detailed estimate data can be found on the Evolus Inc (EOLS) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Evolus Inc's (EOLS, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Evolus Inc (EOLS, Financial) in one year is $21.15, suggesting a upside of 109.2% from the current price of $10.11. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Evolus Inc (EOLS) Summary page.
